Patient Characteristics
Two hundred eighty-five AF patients treated with NOACs (dabigatran 150
mg/110 mg b.i.d.: n=74/11, rivaroxaban 15 mg/10 mg q.d.: n=54/5,
apixaban 5 mg/2.5 mg b.i.d.: n=43/5, edoxaban 60 mg/30 mg q.d.: n=33/23)
or VKA (n=37) for ≥4 weeks before catheter ablation were eligible. Table
1 summarizes patients’ characteristics. NOACs were prescribed at
appropriate doses in 234 patients (95%) whereas at inappropriate doses
in 14 patients (5%). The average of TTR and PT-INR on the day of the
procedure in patients treated with VKA were 73±37% and 2.1±0.4,
respectively.